DrugBiological
Interferon-alpha2b clinical trials
A product of Interferon alpha-2; its studies count on that page too.
- studies test it
- 5
- open now
- 0
- in phase 3
- 1
- first study started
- 2011
How studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
5 studies that test it; most in 2011 (1)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2020 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 4
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 4
Pontificia Universidad Catolica de Chile (1) · The Camelot Foundation (1) · Tianjin SinoBiotech Ltd. (1) · Leiden University Medical Center (1) · Fox Chase Cancer Center (1)
Often tested with
Tested in the same studies.
Tocilizumab (2) · Hydroxychloroquine (1) · Azithromycin (1) · Doxycycline (1) · Clindamycin (1) · Remdesivir (1) · Methylprednisolone (1) · Losartan (1)
Studies
Open first, then newest update. How each study uses Interferon-alpha2b is read from its arms, and is right about nine times in ten.
Testing it · 5
- Inhaled Interferon α2b for the Treatment of Coronavirus Disease 19 (COVID-19)CompletedPhase 1/2Pontificia Universidad Catolica de ChileNCT04988217Written as Interferon-Alpha2B
- The Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolCompletedPhase 2/3The Camelot FoundationNCT04349410Written as Interferon-Alpha2B
- Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)TerminatedPhase 1/2Fox Chase Cancer CenterNCT02447887Written as Pegylated IFN-alpha 2b
- Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Chinese Healthy VolunteersCompletedPhase 1Tianjin SinoBiotech Ltd.NCT02781753Written as Human Serum Albumin/interferon alpha2b
- Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian CancerCompletedPhase 1/2Leiden University Medical CenterNCT01637532Written as tocilizumab and interferon alpha 2-b